All In Biotech

NDA 021132 · Pfizer

Zyvox

Linezolid · Oral · Oxazolidinone Antibacterial

Priority review

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Apr 18, 2000

Approved uses

5

Original approval plus efficacy supplements

Registered trials

179

68 Phase 3, 26 recruiting

FAERS reports

30,255

27,449 serious, 5,532 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 3, 2026.

ZYVOX is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia ( 1.1 ); Community-acquired pneumonia ( 1.2 ); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis ( 1.3 ); Uncomplicated skin and skin structure infections ( 1.4 ); Vancomycin-resistant Enterococcus faecium infections. ( 1.5 ) Limitations of Use ( 1.6 ) : • ZYVOX is not indicated for the treatment of Gram-negative infections. • The safety and efficacy of ZYVOX formulations given for longer than 28 days have not been evaluated in controlled clinical trials. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX formulations and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.7 ) 1.1 Nosocomial Pneumonia ZYVOX is indicated for the treatment of nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates) or Streptococcus pneumoniae [ see Clinical Studies (14) ]. 1.2 Community-acquired Pneumonia ZYVOX is indicated for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae , including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible isolates only) [ see Clinical Studies (14) ]. 1.3 Complicated Skin and Skin Structure Infections ZYVOX is indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus...

Mechanism: ZYVOX is an antibacterial drug [ see Microbiology (12.4) ].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 12, 2005 Supplement 9 · Efficacy · priority review LetterLabel
  • Jun 23, 2004 Supplement 6 · Efficacy · priority review LetterLabel
  • Jul 22, 2003 Supplement 4 · Efficacy Letter
  • Dec 19, 2002 Supplement 3 · Efficacy · priority review LabelReviewLetter
  • Apr 18, 2000 Original approval · Type 3 - New Dosage Form · priority review LabelReviewLetter
1 products under this application
  • ZYVOX · LINEZOLID 100MG/5ML · FOR SUSPENSION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Linezolid" as an intervention, any sponsor and status, largest first.

All 179 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use2,626
  • thrombocytopenia2,242
  • drug ineffective2,126
  • anaemia1,777
  • drug interaction1,460
  • nausea1,450
  • vomiting1,158
  • platelet count decreased1,088
  • diarrhoea1,084
  • lactic acidosis1,040
  • pyrexia1,039
  • neuropathy peripheral1,019

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004326
2005305
2006546
2007525
2008439
2009451
2010897
2011780
2012690
2013625
2014563
2015587
2016951
20171,167
20182,670
20192,298
20202,380
20211,976
20222,407
20232,351
20242,577
20252,554
20262,190

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zyvox (Linezolid)

2024 spending

$41K

Beneficiaries

22

23 claims

Per beneficiary

$1,871

$74.67 per unit

View as table
YearSpending
2020$358,179
2021$69,591
2022$96,107
2023$50,086
2024$41,157

Part D: Zyvox (Linezolid In Dextrose 5%)

2024 spending

$33K

Beneficiaries

60

110 claims

Per beneficiary

$542

$0.12 per unit

View as table
YearSpending
2020$74,186
2021$48,776
2022$31,067
2023$29,011
2024$32,523

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 459 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.